Make us a preferred source
Please login to bookmark Close

Bayer has lost its battle to protect top-selling blood thinner Xarelto from generic competition, with the Full Court finding two patents for the drug are invalid.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au